Raymond James Financial’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273M Buy
3,160,652
+72,662
+2% +$6.05M 0.07% 237
2026
Q2
$208M Buy
3,087,990
+305,363
+11% +$20.3M 0.06% 302
2026
Q1
$174M Buy
2,782,627
+330,415
+13% +$23M 0.05% 320
2025
Q4
$163M Sell
2,452,212
-889,408
-27% -$57.5M 0.05% 329
2025
Q3
$225M Sell
3,341,620
-37,496
-1% -$2.97M 0.07% 245
2025
Q2
$295M Buy
3,379,116
+24,059
+0.7% +$1.89M 0.1% 185
2025
Q1
$229M Buy
3,355,057
+631,088
+23% +$51.5M 0.09% 215
2024
Q4
$212M Buy
+2,723,969
New +$202M 0.08% 224

Other funds holding DXCM

Raymond James Financial's DXCM Position: Q3 2026 in Review

Raymond James Financial increased its DexCom (DXCM) stake by 2.4% in Q3 2026, buying an estimated $6.05M and bringing the position to 3,160,652 shares worth $273M. The position accounts for 0.07% of the portfolio, ranked #237.

Raymond James Financial first reported a position in DXCM in Q4 2024 and has held it in 8 quarters since. The position peaked at $295M in Q2 2025. 1,049 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Raymond James Financial held 3,160,652 shares of DexCom worth $273M as of Q3 2026.
  • Raymond James Financial bought 72,662 DexCom shares in Q3 2026, an estimated $6.05M.
  • DexCom made up 0.07% of Raymond James Financial's portfolio in Q3 2026, its #237 holding.
  • Raymond James Financial first reported a position in DexCom in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's DexCom position peaked at $295M in Q2 2025.
  • 1,049 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.